Analysts Anticipate Marinus Pharmaceuticals Inc (MRNS) Will Post Earnings of -$0.14 Per Share
Equities analysts expect that Marinus Pharmaceuticals Inc (NASDAQ:MRNS) will announce earnings of ($0.14) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Marinus Pharmaceuticals’ earnings. Marinus Pharmaceuticals posted earnings of ($0.15) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 6.7%. The firm is scheduled to announce its next earnings results on Tuesday, October 30th.
On average, analysts expect that Marinus Pharmaceuticals will report full-year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($0.76) to ($0.66). For the next fiscal year, analysts forecast that the business will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.88) to ($0.65). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Marinus Pharmaceuticals.
Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.09).
Shares of Marinus Pharmaceuticals stock opened at $9.62 on Friday. The stock has a market cap of $379.31 million, a price-to-earnings ratio of -12.03 and a beta of 2.59. Marinus Pharmaceuticals has a 12-month low of $3.31 and a 12-month high of $9.87.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Northern Trust Corp boosted its stake in shares of Marinus Pharmaceuticals by 625.7% in the 2nd quarter. Northern Trust Corp now owns 386,864 shares of the biopharmaceutical company’s stock valued at $2,736,000 after purchasing an additional 333,555 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Marinus Pharmaceuticals by 190.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 106,560 shares of the biopharmaceutical company’s stock valued at $754,000 after purchasing an additional 69,863 shares in the last quarter. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Marinus Pharmaceuticals in the 2nd quarter valued at approximately $363,000. VHCP Management II LLC bought a new position in Marinus Pharmaceuticals in the 2nd quarter valued at approximately $2,441,000. Finally, BlackRock Inc. raised its holdings in Marinus Pharmaceuticals by 316.9% in the 2nd quarter. BlackRock Inc. now owns 2,650,612 shares of the biopharmaceutical company’s stock valued at $18,740,000 after buying an additional 2,014,774 shares during the last quarter. Institutional investors own 63.64% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
Read More: What is a conference call?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.